Home / Resources / Gene, Cell, + RNA Therapy Landscape Report Q1 2024 Quarterly Data Report

Gene, Cell, + RNA Therapy Landscape Report Q1 2024 Quarterly Data Report

Report
Commercial
a person in a lab coat holding a plastic container with blue circles

In Q1 2024, there were more than 4,000 gene, cell, and RNA therapies in development. The field earned the approval of three new therapies — a CAR-T therapy for myeloma in China, an AAV gene therapy for hemophilia B in Canada, and an autologous cell therapy for melanoma in the United States.

Related products
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape
Professional using a laptop device to access Trialtrove for trial insights and strategy.
Trialtrove
The go-to resource for informing clinical trial strategy, design and execution
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline

Related Resources

PDF preview of the ASGCT Citeline Q4 2023 Report.
JAN 12, 2024
Report
Commercial

Gene, Cell, + RNA Therapy Landscape Q4 2023 Report

The data report from ASGCT and Citeline for Q4 2023 includes pipelines for gene therapy, RNA therapy, and cell therapy plus dealmaking and catalysts.

Clinical-resource-ISCT Report_resource-card-thumbnail
JUN 01, 2023
Report
Clinical

Cell and Gene Therapy Global Regulatory Report

The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.

PDF preview of the Annual Pharma R&D 2024 White Paper.
White paper
Clinical

R&D Annual Review

The 32nd edition of our comprehensive R&D climate report. We've analyzed over 22,000 drugs in development to help you determine where the outlook is sunny, and where the storm clouds are gathering.

View All Resources